抽象的
预期经常暴露于抗血清胰岛素药物上调气道肌肉蛋白受体,如果停止或省略治疗,可能会导致气道阻塞的瞬态增加。在治疗期间,在治疗期间(FEV1)和三个约束激动剂的呼吸反应性(作为引起20%的激动剂的激动剂的激励剂量,在呼吸呼气流程中检查了峰值呼气流量(PEFR)(作为引起20%的激动剂的激动剂,导致FEV1,(PD20)的促进剂量为20%)常规吸入的IPratropium溴化物,13例受轻度稳定哮喘的受试者。受试者吸入安慰剂和奥普罗吡啶,80 microg Q.I.D。在每次治疗期之前和之后的14天的交叉时尚中持续14天。受试者在整个研究中记录症状分数和PEFR,并且在停止治疗之前和之后测量FEV1和PD20到组胺,甲素和甲硫酸盐。与基线相比,在胰腺炎停止后,FEV1比安慰剂在安慰剂之后较低,最后剂量后30小时(差异190mL; 95%置信区间(95%CI)310-70ml; P <0.02)。FEV1在6-10天以后测量,没有显着差异。在第15天(在最后剂量之后19-37小时19-37小时后,PEFR在IPratropium停止后显着降低)(平均差异4.6%; 95%CI 1.6-7.5%; P <0.01)但不是在第16天。在停止治疗后,PD20组胺,甲素和甲基氨基,甲素和硫代脲晶,症状评分或救援支气管扩张剂使用无显着变化。 Thus, transient bronchoconstriction was found around 30 h after cessation of regular therapy with inhaled ipratropium for 2 weeks. The mechanism is unclear, as no evidence of muscarinic receptor upregulation was found. Although the changes were small and unlikely to be important for most patients, the results of this study indicate that the timing of lung function measurements relative to the last dose of ipratropium is important when interpreting the course of lung function in long-term studies.